Immune Design Appoints Stephen R. Brady Chief Business Officer

SEATTLE and SAN FRANCISCO, Sept. 26, 2013 /PRNewswire/ -- Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced the appointment of Stephen R. Brady as its Chief Business Officer.

(Logo: http://photos.prnewswire.com/prnh/20130926/SF87058LOGO)

Mr. Brady brings extensive experience to lead Immune Design's business functions, including strategic planning and corporate development activities. His appointment in this new position is a reflection of the Company's maturing immune-based therapeutic programs and productive platform technology.

"Steve is an experienced and accomplished executive with a successful track record of executing successful business development and corporate strategies," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer at Immune Design. "He is a key addition to our expanded management team and will play an important role in advancing and expanding our strategic activities."

"Immune Design's combination of both novel antigen-specific and innate immunity approaches is an exciting potential advancement in the area of cancer immunotherapy," said Mr. Brady.  "I look forward to working with the team to move existing programs forward and further expand the reach of the company's platform technology in oncology, infectious disease and allergies."

Most recently, Mr. Brady served as Chief Business Officer for 3-V Biosciences, Inc., where he led business and operations activities, including finance, legal, corporate communications and strategic portfolio planning. Previously, he served as Vice President of Corporate Development for Proteolix, Inc., where he was primarily responsible for corporate development and legal affairs, including the sale of the Company to Onyx Pharmaceuticals for $851M in 2009. Prior to his tenure with Proteolix, Mr. Brady served as Senior Corporate Counsel at Lexicon Pharmaceuticals, Inc., where he served primarily in business development and legal capacities.  Mr. Brady was also a Vice President with Lazard Venture Advisors, a division of Lazard Freres & Co, LLC., and an associate in the New York and San Francisco offices of Morrison & Foerster LLP.  Mr. Brady received a B.A. in English from the University of Oregon and a LL.M. from New York University School of Law.

The Immune Design Approach

Immune Design's immunotherapy approach is designed to both activate and deliver tumor antigens to dendritic cells in vivo to trigger specific, broad, and effective anti-tumor immune responses. The company's pipeline includes LV305 and G305 product candidates generated from two distinct technologies. Immune Design's proprietary lentiviral vector platform selectively targets dermal DCs in vivo to induce a powerful and durable pool of tumor specific cytotoxic T lymphocytes (CTLs). The company's synthetic TLR4 agonist, GLA, is a powerful inducer of innate immunity on its own and also triggers a potent and specific cellular and humoral anti-tumor immune response when it is combined with a tumor antigen. The LV305 and G305 product candidates will be individually tested in parallel in oncology indications and, upon demonstration of safety and immunogenicity, will then be tested in combination. These technologies may be applied in other allergy and infectious disease settings as well.

About Immune Design
Immune Design is a privately held, clinical stage biotechnology company based in Seattle, WA.  Immune Design brings together some of the world's leaders in the field of molecular immunology to develop a synergistic platform of next-generation therapeutic vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. The company employs leading-edge technologies that target dendritic cells for more precise activation of the immune response. These include a novel lentiviral vector engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo and a TLR4 agonist that activates dendritic cells by up-regulating key molecules for efficient antigen presentation and produces Th1 cytokines to enhance the immune response. For more information, visit www.immunedesign.com.

SOURCE Immune Design

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED